These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 30615446)
1. Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor. Shi L; Zhong Z; Li X; Zhou Y; Pan Z J Med Chem; 2019 Jan; 62(2):1054-1066. PubMed ID: 30615446 [TBL] [Abstract][Full Text] [Related]
2. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket. Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070 [TBL] [Abstract][Full Text] [Related]
3. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors. Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors. He L; Shao M; Wang T; Lan T; Zhang C; Chen L Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195 [TBL] [Abstract][Full Text] [Related]
6. Discovery of highly potent, selective, covalent inhibitors of JAK3. Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibitors of the Janus kinase Jak3--Are they effective? Thoma G; Drückes P; Zerwes HG Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444 [TBL] [Abstract][Full Text] [Related]
8. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931 [TBL] [Abstract][Full Text] [Related]
9. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors. Dai J; Yang L; Addison G Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716 [TBL] [Abstract][Full Text] [Related]
10. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold. Forster M; Chaikuad A; Dimitrov T; Döring E; Holstein J; Berger BT; Gehringer M; Ghoreschi K; Müller S; Knapp S; Laufer SA J Med Chem; 2018 Jun; 61(12):5350-5366. PubMed ID: 29852068 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. Forster M; Gehringer M; Laufer SA Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Dymock BW; See CS Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873 [TBL] [Abstract][Full Text] [Related]
13. ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling. Thorarensen A; Banker ME; Fensome A; Telliez JB; Juba B; Vincent F; Czerwinski RM; Casimiro-Garcia A ACS Chem Biol; 2014 Jul; 9(7):1552-8. PubMed ID: 24814050 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors. Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331 [TBL] [Abstract][Full Text] [Related]
15. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802. Norman P Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636 [TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808 [TBL] [Abstract][Full Text] [Related]
18. Development of Selective Covalent Janus Kinase 3 Inhibitors. Tan L; Akahane K; McNally R; Reyskens KM; Ficarro SB; Liu S; Herter-Sprie GS; Koyama S; Pattison MJ; Labella K; Johannessen L; Akbay EA; Wong KK; Frank DA; Marto JA; Look TA; Arthur JS; Eck MJ; Gray NS J Med Chem; 2015 Aug; 58(16):6589-606. PubMed ID: 26258521 [TBL] [Abstract][Full Text] [Related]